Influences of Propofol-Remifentanil and Propofol-Epidural Anesthesia Combination on Dynamic Respiratory Tests in Laparoscopic Morbid Obesity Surgery
Objectives: Morbid obesity (MO) is an important risk factor for respiratory diseases. The aim of this study changes are observed between the preoperative and postoperative pulmonary functions of morbid obese patients undergoing laparoscopic sleeve gastrectomy with propofol-remifentanil infusion anesthesia(TIPA) and propofol-epidural anesthesia(EDIPA) under BIS control.
Methods: A total of 52 patients who were to undergo sleeve gastrectomy for MO were divided into two groups for this prospective randomized double-blind study. Propofol infusion was administered to both groups (initial dose 10 mg kg hour); the bispectral index (BIS) was maintained between 40-50 for the maintenance dose, and the hemodynamic parameters were considered. Remifentanil was administered at a dose of 25 ughour via TCA (target controlled analgesia) pump in Group P. In Group E, additionally, 0.0125% bupivacaine was administered with the TCA device at a dose of 8 ml/hour via the epidural route. PFT was performed 4 hours preoperatively and at the 4th hour beginning from the time when the postoperative modified Aldrete scores (MAS) were 9.
Results: MAS time and the amount of propofol used were found to be significantly lower in postoperative period in Group E. FEV1 and FVC were found to be significantly higher in the postoperative period in Group E. Conclusion: PFT is better in the early postoperative period in cases whom epidural anesthesia is administered.
1.Bonsaksen T, Fagermoen MS, Lerdal A.Trajectories of physical and mental health among persons with morbid obesity and persons with COPD: a longitudinal comparative study. J Multidiscip Healthc 2016;9:191–200. [CrossRef]
2. Navarro E, Funtikova AN, Fíto M, Schröder H.Can metabolically healthy obesity be explained by diet, genetics, and inflammation? Mol Nutr Food Res 2015;59:75–93. [CrossRef]
3. Dixon JB.It's up to us, contributors, reviewers, and editors, to set and maintain high standards of scientific quality and review. Comment on: The impact of metabolic parameters on the change of pulmonary function in obese patients. Surg Obes Relat Dis 2014;10:367–8. [CrossRef]
4. Ortiz VE, Vidal-Melo MF, Walsh JL. Strategies for managing oxygenation in obese patients undergoing laparoscopic surgery. Surg Obes Relat Dis 2015;11:721–8. [CrossRef]
5. Pirrone M, Fisher D, Chipman D, Imber DA, Corona J, Mietto C et al. Recruitment Maneuvers and Positive End-Expiratory Pressure Titration in Morbidly Obese ICU Patients. Crit Care Med 2016;44:300–7. [CrossRef]
6. Robinson PD. Obesity and its impact on the respiratory system. Paediatr Respir Rev 2014;15:219–26. [CrossRef]
7. Lehavi A, Sandler O, Mahajna A, Weissman A, Katz YS. Comparison of Rhabdomyolysis Markers in Patients Undergoing Bariatric Surgery with Propofol and Inhalation-based Anesthesia. Obes Surg 2015;25:1923–7. [CrossRef]
8. Cortínez LI, De la Fuente N, Eleveld DJ, Oliveros A, Crovari F, Sepulveda P, et al. Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg 2014;119:302–10. [CrossRef]
9. Short TG, Hannam JA, Laurent S, Campbell D, Misur M, Merry AF, et.al.Refining Target-Controlled Infusion: An Assessment of Pharmacodynamic Target-Controlled Infusion of Propofol and Remifentanil Using a Response Surface Model of Their Combined Effects on Bispectral Index.Anesth Analg 2016;122:90–7. [CrossRef]
10. Chidambaran V, Venkatasubramanian R, Sadhasivam S, Esslinger H, Cox S, Diepstraten J, et al. Population pharmacokinetic-Pharmadynamic modeling and dosing stimulation of propofol maintenance anesthesia in severely obese adolescents. Paediatr Anaesth 2015;25:911–23. [CrossRef]
11. Cortinez LI, De la Fuente N, Eleveld DJ, Oliveros A, Crovari F, Sepulveda P, et al. Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg 2014;119:302–10. [CrossRef]
12. Ingrande J, Lemmens HJ. Anesthetic Pharmacology and the Morbidly Obese Patient. Curr Anesthesiol Rep 2013;3:10–7.
13. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther 2014;39:584–608. [CrossRef]
14. Van Kralingen S, Van de Garde EM, Van Dongen EP, Diepstraten J, Deneer VH, van Ramshorst B, et.al. Maintenance of anesthesia in morbidly obese patients using propofol with continuous BIS-monitoring: a comparison of propofol-remifentanil and propofol-epidural anesthesia. Acta Anaesthesiol Belg 2011;62:73–82.
15. Marseu K, Slinger P. Peri-operative pulmonary dysfunction and protection. Anaesthesia 2016;71 Suppl 1:46–50. [CrossRef]
16. Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg 2011;113:57–62. [CrossRef]
17. Attaur-Rasool S, Shirwany TA. Body mass index and dynamic lung volumes in office workers. J Coll Physicians Surg Pak 2012;22:163–7.
18. Mafort TT, Rufino R, Costa CH, Lopes AJ. Obesity: systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med 2016.
19. Melo LC, Silva MA, Calles AC. Obesity and lung function: a sys-tematic review. Einstein (Sao Paulo) 2014;12:120–5. [CrossRef]
20. Misquith JC, Rao R, Ribeiro KS. Serial Peak Expiratory Flow Rates in Patients Undergoing Upper Abdominal Surgeries Under General Anaesthesia and Thoracic Epidural Analgesia. J Clin Diagn Res 2016;10:UC01–4. [CrossRef]
21. Yilmaz MZ, Sarihasan BB, Kelsaka E, Taş N, Çaglar Torun A, Köksal E et.al.Comparison of the analgesic effects of paracetamol and tramadol in lumbar disc surgery. Turk J Med Sci 2015;45:438–42. [CrossRef]
22. Gunay S, Eser I, Ozbey M, Agar M, Koruk I, Kurkcuoglu IC. Evaluation of two different respiratory physiotherapy methods after thoracoscopy with regard to arterial blood gas, respiratory function test, number of days until discharge, cost analysis, comfort and pain control. Niger J Clin Pract 2016;19:353–8.
23. Mafort TT, Madeira E, Madeira M, Guedes EP, Moreira RO, de Mendonça LM, et al. Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome. Obes Surg 2014;24:232–40. [CrossRef]
24. Mafort TT, Madeira E, Madeira M, Guedes EP, Moreira RO, de Mendonça LM, et al. Intragastric balloon for the treatment of obesity: evaluation of pulmonary function over a 3-month period Lung 2012;190:671–6. [CrossRef]